The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Abstract
Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is one of the major cellular signaling pathways play an important role in basic intracellular functions. The PI3K/Akt/mTOR pathway regulates cell proliferation, growth, cell size, metabolism, and motility. Component genes of this pathway were extensively studied and found to be commonly activated in human cancer. Inhibition of this pathway is shown to have better regression of human tumors and being studied in preclinical and evaluated in many clinical trials at various levels. Some inhibitors of this pathway are approved by the food and drug administration after their potent activity and their effect overweighed the toxicities/side effects. This review discusses the recent trends in exploiting the PI3K/Akt/mTOR pathway towards the molecular targeted therapy using small molecule inhibitors in human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Insulin Receptor Signaling in Normal and Insulin-Resistant States
Boucher, J., Kleinridders, A., & Kahn, C. R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009191 · Cited by 1,473
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., & Gotoh, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109745200 · Cited by 617
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Sianna Castillo, S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 585
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
mTOR in aging, metabolism, and cancer
Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 449
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
Aromatase, aromatase inhibitors, and breast cancer
Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.001 · Cited by 401
Mechanisms of PTEN loss in cancer: It’s all about diversity
Álvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.001 · Cited by 401
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Mutations of the human PTEN gene
Bonneau, D., & Longy, M. (2000) · Human Mutation · doi:10.1002/1098-1004(200008)16:2<109::aid-humu3>3.0.co;2-0 · Cited by 333
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wu, W.-I., Voegtli, W. C., Sturgis, H. L., Dizon, F. P., Vigers, G. P. A., & Brandhuber, B. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012913 · Cited by 331
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Wagle, N., Grabiner, B. C., Van Allen, E. M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J. A., Guo, Y., Swanson, S. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321
de Bono, J. S., De Giorgi, U., Rodrigues, D. N., Massard, C., Bracarda, S., Font, A., Arranz Arija, J. A., Shih, K. C., Radavoi, G. D., Xu, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0981 · Cited by 311
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
Carnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Janku, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.005 · Cited by 243
Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 228
PIK3CA in cancer: The past 30 years
Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 216
Bhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 198
PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn, Jx, Lee, Kiley, Loh, K. W.-J., Yoon-Sim, & Yap (2015) · 癌症生物学与医学:英文版 · Cited by 185
Molife, L. R., Yan, L., Vitfell-Rasmussen, J., Zernhelt, A. M., Sullivan, D. M., Cassier, P. A., Chen, E., Biondo, A., Tetteh, E., Siu, L. L., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-1 · Cited by 183
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 156
Banerji, U., Dean, E. J., Fidalgo, J. A. P., Batist, G., Bedard, P. L., You, B., Westin, S. N., Kabos, P., Garrett, M. D., Tall, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2260 · Cited by 154
Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers
Parikh, C., Janakiraman, V., Wu, W., Foo, C. K., Kljavin, N. M., Chaudhuri, S., Stawiski, E. W., Lee, B., Lin, J. M., Li, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204384109 · Cited by 151
Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
Crouthamel, M., Kahana, J. A., Korenchuk, S., Zhang, S., Sundaresan, G., Eberwein, D. J., Brown, K. K., & Kumar, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1253 · Cited by 137
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
Greenwell, I. B., Ip, A., & Cohen, J. B. (2017) · PubMed · Cited by 119
Targeting PI3K signaling in cancer: Challenges and advances
Santis, M. C. D., Gulluni, F., Campa, C. C., Martini, M., & Hirsch, E. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.03.003 · Cited by 110
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
Waldner, M., Fantus, D., Solari, M. G., & Thomson, A. W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12893 · Cited by 106
Fox, E. M., Kuba, M. G., Miller, T. W., Davies, B. R., & Arteaga, C. L. (2013) · Breast Cancer Research · doi:10.1186/bcr3449 · Cited by 92
A kinase-independent function of AKT promotes cancer cell survival
Vivanco, I., Chen, Z. C., Tanos, B. E., Oldrini, B., Hsieh, W.-Y., Yannuzzi, N. A., Campos, C., & Mellinghoff, I. K. (2014) · eLife · doi:10.7554/elife.03751 · Cited by 91
Engineering CAR-T Cells for Improved Function Against Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02493 · Cited by 86
Espósito, A., Viale, G., & Curigliano, G. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0034 · Cited by 86
Ma, C. X., Sanchez, C. G., Gao, F., Crowder, R. J., Naughton, M., Pluard, T., Creekmore, A. N., Guo, Z., Hoog, J., Lockhart, A. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2160 · Cited by 77
Liu, Y., Yang, F., Zou, S., & Qu, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01520 · Cited by 77
Genetic deregulation of the PIK3CA oncogene in oral cancer
Murugan, A. K., Munirajan, A. K., & Tsuchida, N. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.005 · Cited by 75
Ma, C. X., Suman, V. J., Goetz, M. P., Northfelt, D., Burkard, M. E., Ademuyiwa, F. O., Naughton, M., Margenthaler, J. A., Aft, R., Gray, R. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1260 · Cited by 75
Hassan, B., Akçakanat, A., Sangai, T., Evans, K. W., Adkins, F. C., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2337 · Cited by 65
Aghajanian, C. A., Bell‐McGuinn, K. M., Burris, H. A., Siu, L. L., Stayner, L.-A., Wheler, J. J., Hong, D. S., Kurkjian, C. D., Pant, S., Santiago-Walker, A., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0591-z · Cited by 58
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
Mortensen, D. S., Fultz, K. E., Xu, S., Xu, W., Packard, G. K., Khambatta, G., Gamez, J. C., Leisten, J. C., Zhao, J., Apuy, J. L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1052 · Cited by 54
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349
Pei, Z., Blackwood, E. R., Liu, L., Malek, S., Belvin, M. P., Koehler, M. F. T., Ortwine, D. F., Chen, H., Cohen, F., Kenny, J. R., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003132 · Cited by 48
Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*
Murugan, A. K., Alzahrani, A. S., & Xing, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399485 · Cited by 47
Self-citationIs There a Future for AKT Inhibitors in the Treatment of Cancer?
Jansen, V. M., Mayer, I. A., & Arteaga, C. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0100 · Cited by 47
Moore, K. N., Bauer, T. M., Falchook, G. S., Chowdhury, S. K., Patel, C. A., Neuwirth, R., Enke, A. S., Zohren, F., & Patel, M. R. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000291 · Cited by 45
Identification and characterization of two novel oncogenic mTOR mutations
Murugan, A. K., Liu, R., & Xing, M. (2019) · Oncogene · doi:10.1038/s41388-019-0787-5 · Cited by 37
Abu-Khalaf, M. M., Baumgart, M. A., Gettinger, S. N., Doddamane, I., Tuck, D. P., Hou, S., Chen, N., Sullivan, C. A. W., Lezon-Geyda, K., Zelterman, D. A., et al. (2015) · Cancer · doi:10.1002/cncr.29254 · Cited by 15
Absence of somatic mutations of the mTOR gene in differentiated thyroid cancer
Murugan, A. K., Humudh, E. A., Qasem, E., Al‐Hindi, H., Almohanna, M., Hassan, Z. K., & Alzahrani, A. S. (2015) · Meta Gene · doi:10.1016/j.mgene.2015.08.005 · Cited by 14
Self-citationPTEN: An Intercellular Peacekeeper?
Leslie, N. R. (2012) · Science Signaling · doi:10.1126/scisignal.2003685 · Cited by 12
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Health Benefits and Pharmacological Properties of Stigmasterol
Bakrim, S., Benkhaira, N., Bourais, I., Benali, T., Lee, L.-H., El Omari, N., Sheikh, R. A., Goh, K. W., Ming, L. C., & Bouyahya, A. (2022) · Antioxidants · doi:10.3390/antiox11101912 · Cited by 422
Metadata
- Authors
- Alzahrani, A. S.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 59
- Pages
- 125-132
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2962354828
- Cited by
- 1,054
- References
- 68
- FWCI
- 31.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.